10:00 Stefan Krauss, Hybrid Technology Hub
Welcome
10:10 Kevin Healy, University of California, Berkeley
Human Tissue Chips for Drug Development, Disease Modeling, and More…
10:40 Paul Gatenholm, Chalmers University of Technology
3D Bioprinting of Vascular Tissue and Organs for Clinical Applications on Earth and for Space Exploration
11:00 Sam Wall, Simula
Data driven modeling for mechanistic insight and uncertainty quantification in cardiac microphysiological systems.
11:20 Erik Andrew Johannessen, University of South-Eastern Norway
The differentiation of human mesenchymal stem cells in a microfluidic device
11:40 Break
12:00 Espen Melum, Oslo University Hospital
Organoids in bile duct immunology
12:20 Viola Lobert, CanCell Centre of Excellence
Elucidating the role of tumour suppressors in epithelial morphogenesis using organoids
12:40 Hanne Scholz, Hybrid Technology Hub, Center of Excellence
Adipose-derived stem cells improve 3D bioprinted pancreatic islets
13:00 - 13:30 Panel discussion, "The future of OoC". Kevin Healy, Sam Wall, Hanne Scholz, Stefan Krauss.
Biographies:
Kevin E. Healy is an international leader working at the interface between stem cells and materials science to develop dynamic engineered systems to explore both fundamental biological phenomena and new applications in translational medicine. His group currently conducts research in the areas of bioinspired stem cell microenvironments to control stem cell lineage specification and self-organization into microtissues or organoids; bioinspired systems for regenerative medicine; biological interfaces; and, microphysiological systems for drug development, gene editing, and environmental toxicity screening. Professor Healy is an elected Fellow of AIMBE, AAAS, FBSE, BMES, and recently received an Alexander von Humboldt Foundation Award. He has chaired the Gordon Research Conference on Biomaterials and Biocompatibility, and has been honored with the 2011 Clemson award for outstanding contributions to basic biomaterials science. He is a named inventor on numerous issued United States and international patents relating to biomaterials, therapeutics, stem cells, and medical devices, and has founded several companies to develop these systems for applications in biotechnology and regenerative medicine.
Samuel Wall is a Chief Research Scientist at Simula Research Laboratory and leader of the Computational Physiology Department. He recieved his Ph.D. in Bioengineering jointly from the University of California, Berkeley and the University of California, San Francisco and has worked since at the interface between biology and computation, working to establish meaningful and impactful applications of computer science in the wet lab, in industry, and in the clinic. He has worked for the past 6 years directing the computational efforts within the Center for Cardiological Innovation, a RCN funded SFI, and recent work has focused on connecting computational expertise at Simula Research Lab with Heart on Chip technologies.
Paul Gatenholm is professor of Biopolymer Technology at Chalmers University of Technology, Founder of 3D Bioprinting Center, and Director of Graduate School at WWSC. He is also Adjunct Professor at Joint School of Biomedical Engineering and Sciences at Virginia Tech and Wake Forest University and Adjunct Professor of Biomaterials at Wake Forest Institute for Regenerative Medicine in Winston-Salem, North Carolina, USA. His research includes biological fabrication through the use of enzymes, cells, and the coordination of biological systems. Dr. Gatenholm is particularly interested in designing and preparing new biomaterials which can replace or regenerate tissue and organs. During past five years he has dedicated his time to development of 3D Bioprinting technology which he believes will revolutionize the field of Medicine. He has published more than 300 papers and edited several books and has more than 9000 citations.
Dr. Espen Melum is a senior scientist and group leader at the Norwegian PSC research center at Oslo University Hospital. He is also a physician at the Section of Gastroenterology at the Department of Transplantation Medicine. He obtained his MD and PhD degree at the university of Oslo followed by post-doctoral training at Harvard University / Brigham and Women’s Hospital. His research group focus on understanding the immunological processes in the bile ducts using mouse models, in vitro models and more recently approaches from regenerative medicine. Dr. Melum received the Anders Jahre’s medical prize for young researchers in 2018
Viola Lobert is a French-Australian scientist who did her undergraduate studies in Australia before coming to Norway and joining the Stenmark lab for her PhD. There she studied the intracellular trafficking of integrins using cell culture, before obtaining funding to do her postdoc on epithelial polarity in tumorigenesis in zebrafish. She spent one year at the WEHI in Australia in the laboratory of Joan Heath before returning to Norway. Since then, she has focused on Caco2 3D culture and is now in the laboratory of Tor Erik Rusten establishing the use of colon organoids to study developmental signaling pathways and their relevance to cancer.
Erik A. Johannessen received his Ph.D. degree in bioelectronics from the University of Liverpool, Liverpool, U.K., in 2002. The Ph.D. project was funded by the Wellcome Trust focusing on the development of ultra-small nanocalorimetric sensors for integration in high-density assay screening of cells. He has since worked as a Post-Doctoral Research Fellow with the Department of Electronic and Electrical Engineering, University of Glasgow, Glasgow, U.K, with specialisation on mobile analytical microsystems before being employed as a Project Manager with Lifecare, Horten, Norway, on the development of an implantable glucose sensor. He is currently a Professor at the University of South-Eastern Norway and has established research activities within BioMEMS, with focus on bioelectronics and biomedical microsystems.
Dr. Hanne Scholz is a principle investigator at Hybrid Technology Hub at the University in Oslo and senior scientist in the Department of Transplantation Medicine at the Oslo University Hospital. She is the director of the human islet isolation facility performing clinical islet transplantation for treatment of type 1 diabetes in Norway. Dr. Scholz leads the research group, which aim to improve and optimize islet isolation, beta cell replacement therapies and improve patient outcomes. Currently, the Scholz lab research focus involves regenerative medicine projects such as the development of new cellular therapies for diabetes using stem cells and creation of functional mini-pancreas for “organ on a chip” platforms.